Media contact details for our global headquarters and USA. For press contacts in our local operating companies please visit our country websites.In you have a media query please use our Contact our team form here.Global Press Office Rachel Jaikaran Head of Global Communications ViiV Healthcare ...
A press release with data from the CUSTOMIZE trial is available on the media page at www.viivhealthcare.com.9 Week 124 findings from the FLAIR study evaluating long-acting cabotegravir and rilpivirine administered monthly for the treatment of HIV-1.8 The phas...
Home Media Press releases ViiV Healthcare announces US FDA appr... December 20 2021 ViiV Healthcare announces US FDA approval of Apretude (cabotegravir extended-release injectable suspension), the first an...
通过阻止HIV进入人体CD4+ T细胞,病毒就无法复制,从而阻止HIV的传播。 今年3月,ViiV Healthcare公布了VH3810109的2a期临床研究数据。在各剂量组中,病毒载量的最大中位数降幅从-0.43 log10 c/mL(范围从-1.29至-0.12;70 mg静脉注射组)变化到-1.72 log10 c/mL(范围从-2.60至-0.60;40 mg/kg静脉注射组),且这...
ViiV Healthcare today announced the release ofAchieving health equity: a roadmap to eliminating disparities, a new report conducted byEconomist Impact, a division of The Economist Group, that explores the opportunities that could be created by eliminating health disparities in the...
Infectious Disease | ViiV Healthcare is providing more than $2.5 million in additional funds for the Collaborative Initiative for Paediatric HIV Education and Research program, or CIPHER, according to a press release from the International AIDS Society. ...
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced positive Week 96 results from the phase III BRIGHTE study of investigation...
ViiV Healthcare has applied to the FDA and the European Medicines Agency (EMA) for approval of the first two-drug antiretroviral (ARV) regimen to treat HIV. The dual combination of ViiV’s integrase strand transfer inhibitor Tivicay (dolutegravir) and Janssen’s non-nucleoside reverse transcriptase...
Dr.Dominique Limet, CEO ViiV Healthcare commented on the news, “Based on the need clearly identified by the Clinton Health Access Initiative in 2012, ViiV Healthcare became the first pharmaceutical company to fully fund the enti...
研发公司:ViiV Healthcare,GSK 最高研发阶段:2期临床 VH4524184是由ViiV与GSK联合开发的第三代长效InSTI疗法。体外研究结果显示,VH4524184的耐药性特征与前几代InSTI药物不同,它能够维持对携带临床相关突变病毒的抗病毒活性,有效对抗第二代InSTI的耐药性。1期临床研究的初步结果表明,VH4524184在血液中的药物浓度可能...